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Abstract: The pain assessment in advanced dementia (PAINAD) appears to be a clinically useful
tool. However, the salivary determination of tumor necrosis factor receptor type II (sTNF-RII) and
secretory IgA (sIgA) as pain biomarkers is still incipient. The aim was to correlate the PAINAD score
with sTNF-RII and sIgA biomarker levels in the saliva of patients with advanced dementia. In this
regard, a cross-sectional study was conducted. The sample consisted of 75 elderly patients with a
clinical diagnosis of dementia and a global deterioration scale (GDS) score of 5 to 7. The PAINAD
scale was determined by a previously trained professional and the collection of salivary samples
was performed using the passive secretion method. Human sTNF-RII and sIgA using ELISA kits.
The results showed a correlation between the PAINAD scale (numeric, binary, and recoded) and
sTNF-RII and sIgA (p < 0.001). No association between the sociodemographic and clinical variables
and the PAINAD scale was found (p > 0.05). Between 97.3% and 96.2% of patients with pain on the
PAINAD scale also showed pain based on the sTNF-RII levels; in all of them, sIgA levels did not fit
the logistic models. Therefore, the correlation highlights the usefulness of this scale and confirms the
usefulness of sTNF-RII and sIgA as biomarkers of pain.
Keywords: dementia; pain; pain assessment in advanced dementia (PAINAD); biomarkers; nursing
1. Introduction
Pain has been defined as “an unpleasant sensory and emotional experience associated
with, or resembling that associated with, actual or potential tissue damage” [1]. Therefore,
pain is not just a sensory process (nociception) [2]. It also involves cognitive and emotional
factors influencing the expression of this experience [3,4].
Pain is common in older people because of the many chronic diseases that often
affect this population group, such as osteoporosis, depression, cancer, or cardiovascular
diseases [5]. It is estimated that approximately 50% of community-dwelling elders [6,7]
and 80% of institutionalized elders have pain [8]. However, despite its high prevalence
among the older population, it is a frequently underdiagnosed and undertreated [9,10].
This undertreatment is more marked among older people with dementia because of the
difficulty in detecting it, and even more when the person cannot communicate effectively
verbally due to disease progression [11,12]. In this case, primary caregivers and health
care professionals are responsible for discerning whether or not the person is suffering
pain [13].
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Therefore, tools such as self-reports can be used to assess the presence and intensity
of pain in early and even moderate stages of dementia, when the person still can abstract
reasoning. In contrast, these pain assessment tools may yield biased results in patients with
advanced dementia due to patients’ lack of ability to understand the concepts assessed
through these tools and, in some cases, even to communicate this pain [14,15]. Conse-
quently, the use of self-reports is restricted to initial or moderate stages of dementia, in the
latter, provided that verbal communication skills are intact [16]. Thus, pain assessment
tools based on direct patient observation emerged to mitigate pain under diagnostics in
patients with dementia and the inability to communicate [17,18]. Today more than 24 tools
are available that are elaborated and validated for this purpose. Of these tools, the PAINAD
scale is considered the most suitable tool for the clinical setting due to its simplicity of
use, extension, and psychometric properties [12,19]. However, this promising scale has
moderate internal consistency and validity. It requires that the assessor has received specific
training to properly assess the pain of the person with advanced dementia [20]. These
limitations reinforce the need to supplement pain assessment in people with dementia and
communication disabilities.
The determination of pain biomarkers is an innovative and useful way of assessing
pain, especially in saliva, as a non-invasive and cost-effective test. Specifically, some
biomarkers of pain, such as salivary cortisol, salivary amylase, testosterone, secretory
IgA (sIgA), or tumor necrosis factor receptor type II (sTNF-RII), have been determined in
previous studies [21–25]. However, among these, sIgA and sTNF-RII have been shown
to be the most reproducible in healthy people [26], also being used to determine pain in
surgical patients [27].
In this context, the potential correlation between the levels of biomarkers (sIgA and
sTNF-RII) and the levels of pain reported by the PAINAD scale could be used in two
directions: On the one hand, to reinforce the usefulness of this scale as a valid tool in the
healthcare setting; and on the other hand, to suggest the determination of these biomarkers
as a complementary method for the evaluation of pain in these patients.
2. Objectives
Correlate the scores of the PAINAD scale with the levels of pain biomarkers sTNF-RII
and sIgA in saliva samples from patients with cognitive impairment.
3. Materials and Methods
3.1. Study Design
This has been a cross-sectional study performed between May 2018 and June 2020.
3.2. Study Setting
The Andalusian network of Primary Healthcare centers (two health districts from two
provinces of Andalusia), four nursing homes and a center specifically dedicated to the care
of dementia patients participated in the study.
3.3. Participants and Selection Criteria
The sample size was calculated for a correlation magnitude of r = 0.3, a statistical
confidence interval (CI) of 95%, a statistical power of 80%, a unilateral approach, and 10%
losses. The result sample size was 75 subjects.
The following inclusion criteria was required for participants:
• Being 65 or older.
• Having a medical diagnosis of dementia or Alzheimer’s disease-like dementia (AD)
with a global deterioration scale (GDS) score between 5 and 7. Those patients who
met DSM-V clinical criteria were diagnosed with dementia, and those who met the
NINCDS/ADRDA (National Institute of Neurological and Communicative Disorders
and Stroke/Alzheimer’s Disease and Related Disorders Association) criteria were
classified as probable or possible AD patients.
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• Being unable to communicate verbally.
• Having received health care at the community level for at least three months because
of the dementia process. In the center dedicated to the care of patients suffering
from AD, the included patients were those who have used this service for at least
three months.
• Having an informed consent signed by a relative or legal representative for the pa-
tient’s inclusion in the study.
All subjects participating in the study were recruited consecutively by the interven-
tional nursing, selecting those who met the previously mentioned criteria from among the
subjects they care for in their health care institutions.
3.4. Study Measures and Data Collection
The main variables were the scores of the Spanish version of PAINAD and the values
in saliva of the sTNF-RII and sIgA biomarkers. To assess the level of pain through the
PAINAD scale, a researcher completed a book for data collection, having previously
received training to ensure the reliability and reproducibility of the data. Likewise, the
researchers received training with regard to how to perform the collection of the saliva
sampler by using the passive secretion method [28]:
1. Subjects were not allowed to practice physical exercise or to eat, ingest any drinks
(except for water), chew gum, brush their teeth, or consume caffeine during the
previous hour preceding the sample collection process.
2. Five minutes before the collection of the sample, as a way to reduce the contamination
of saliva with food debris, the subjects were asked to rinse their mouth with clean
water.
3. Right before starting the sample collection, any saliva present in the mouth at that
time should be swallowed.
4. Afterwards, the saliva accumulated in their mouths for 5 min was deposited in a
collection tube, 1 mL being the minimum volume required. In the case of the 5 mL
collection tube being filled before those 5 min, the corresponding amount of time
elapsed was recorded.
Saliva samples were collected under supervision in a clinical setting, between 09:00 am
and 10:00 am and ensuring it always was done before the intake of the morning medication.
After collection, the samples were put under refrigeration and subsequently frozen (at
−80 ◦C, to be concise) and kept in that state until the analysis was carried out.
In addition, sociodemographic variables (such as gender, age, and marital status)
and clinical variables related to pain were collected from the patient’s medical records.
Furthermore, the GDS and the level of autonomy in basic activities of day-to-day life,
measured by the Barthel index, were determined by the research team at data collection or,
in the cases in which that information was available (and not older than three months), it
was collected from the clinical record.
3.5. Determination of sTNF-RII and IgA
ELISA kits were used to determine sTNF-RII and sIgA levels in saliva. Specifically,
sTNF-RII levels were measured through the Human sTNF-RII Quantikine ELISA kit (R &
D Systems, Minneapolis, MN, USA) and sIgA values were determined utilizing the sIgA
ELISA kit (Salimetrics LLC, State College, Pennsylvania, PA, USA). In addition, Bradford’s
method was the one used for the determination of total protein levels in saliva, in order to
standardize the data.
3.6. Data Analysis
Descriptive statistics were used to characterize the sample. In this sense, for quantita-
tive variables, the following metrics were calculated: mean and its corresponding 95% CI,
standard deviation (SD), minimum, maximum, interquartile range (IQR), median, and the
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number of observations. On the other hand, regarding qualitative variables, the correspond-
ing frequency distributions were determined (both absolute and relative frequencies).
The matrix of polyserial correlations and the appropriate hypothesis contrasts were
the tools of choice to evaluate the association between the levels of the biomarkers under
study and the PAINAD scale.
Then, polyserial correlations and the χ2 coefficient with their corresponding signif-
icance levels were obtained to evaluate the potential relationships of demographic and
clinical variables with biomarkers and PAINAD scores.
Finally, in the case of detecting some kind of relationship between these variables,
they were included in all logit and logistic multinomial models, in order to evaluate their
relative influence on the fact that pain appears or not, and its corresponding degree.
This logit model was utilized with the goal of stablishing which saliva biomarker
affects more the pain condition, and multinomial logistic models were considered to
evaluate which of the biomarkers had the biggest influence on pain levels.
The statistical package SPSS (V.22, IBM, Armonk, NY, United States) was employed
for the majority of calculations mentioned previously, and the R software to determine the
coefficients of polyserial correlations. Through all this statistical analysis, a significance of
5% was assumed.
3.7. Ethical Aspects
The study was carried out following the principles stablished in the Belmont report
and the Helsinki Declaration (updated at the Seoul Assembly in 2008) for biomedical
research. A Patient Information Sheet (PIS) was handed over to all family members or
legal representatives of the candidates to offer them information regarding the general
aspects of the study. Written informed consents were obtained and voluntarily signed by
the patient’s relative or legal representative. All participants were allowed to withdraw
consent to participate at any time during the development of the process.
Data confidentiality was always guaranteed, and so was the subject’s anonymity.
In this sense, the study received the permission of all participating centers, as well as
the approval of the Ethics Committee for Research of Andalusia (Acta nº 271, ref. 3672,
approved on 5 December 2017).
4. Results
4.1. Sample Characteristics
A total of 75 participants were studied, of whom 59 (78.7%) were women. The overall
mean age was 84.41 (7.44) years, 95% CI (82.70–86.13), and the range was 65–95 years.
Regarding the marital status, a total of 68% of the sample were surviving spouses. Con-
cerning the place of residence, 64 subjects lived in a rural area. In addition, 69.3% were
institutionalized.
Regarding the diagnosis of dementia, 69.33% had AD, which is, therefore, the most fre-
quent type of dementia. Similarly, regarding the level of cognitive impairment, 34 subjects
had a GDS 7. Furthermore, as for the level of independence for performing basic activities
of daily living, the median Barthel index score was 10 (max = 80 and min = 0).
Only 34 subjects of the total sample were prescribed analgesic treatment for their pain.
The median of the PAINAD scale was 0 (max = 8 and min = 0), 95% CI (0.96–1.95). Fur-
thermore, the median sTNF-RII (pg/mg protein) was 2.56 (max = 684.28 and min = 0.0162)
95% CI (5.84–49.28), whereas the median sIgA (ng/mg protein) determination in 54 of
the participants was 5285.60 (max = 157440.83 and min = 6.49), 95% CI (4439.82–18905.34).
Table 1 shows in detail the sociodemographic and clinical characteristics of the study
subjects. In addition, Figures 1 and 2 show the PAINAD numerical scores and the levels of
sTNF-RII and sIgA, respectively.
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Table 1. Description of the sample.
Variable Totaln = 75
Sociodemographic variables
















Type of dementia n (%)
Alzheimer’s disease 52 (69.33%)
Vascular dementia 8 (10.67%)
Primary degenerative dementia 2 (2.67%)
Mixed dementia 13 (17.33%)
Level of cognitive impairment b n (%)
GDS 5 13 (17.33%)
GDS 6 28 (37.33%)
GDS 7 34 (45.33%)
Level of dependency for basic activities of daily living c n (%)
Moderate dependence 7 (9.3%)
Severe dependence 18(24%)
Total dependence 50 (66.7%)
Prescription of analgesics n (%)
Yes 34 (45.33%)
No 41 (54.67%)
Time consuming analgesics (days)
Me (maximum-minimum) a
471 (4321–5)




sIgA (ng/mg protein) (n = 54)
Me (maximum-minimum) a
5285.60 (157440.83–6.49)
a The median has been calculated given the robustness of this analysis and because the range of possible values is
very wide.b Assessed using the global deterioration scale (GDS).c Assessed using the Barthel index.
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Figure 1. Association between PAINAD numerical score and sTNF-RII (pg/mg protein) values.
Figure 2. Association between pain assessment in advanced dementia (PAINAD) numerical score and sIgA (ng/mg
protein) values.
4.2. Correlation between PAINAD Scale and Sample Characteristics
Concerning the possible association between the PAINAD variable (both the numerical
version of the PAINAD variable, and the binary version and its recoding as: no pain,
possible pain, and pain) and the rest of the sociodemographic variables of the categorical
type, no correlation was found in any case (p > 0.05).
The degree of relationship between PAINAD (numeric) and the rest of the sociodemo-
graphic and clinical numerical variables, measured through the polyserial correlation coef-
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ficient, demonstrated a lack of relationship between the variables considered. Specifically,
the results showed no relationship between PAINAD and age (p = 0.20), time consuming
analgesics (p = 0.94), and Barthel index score (p = 0.21).
Similarly, no relationship has been found between PAINAD (in its binary recoding)
and age (p = 0.11), time consuming analgesics (p = 0.44), and level of dependence for basic
activities of daily living according to the score of the Barthel index (p = 0.21), based on the
calculation of the polyserial correlation coefficient.
Similarly, the polyserial correlation coefficient showed no association between recoded
PAINAD (no pain, possible pain, and pain) and age (p = 0.13), time consuming analgesics
(p = 0.50), and Barthel index score (p = 0.37).
Therefore, the presence or absence of pain (in all grades) is independent of sex, age,
marital status, area (rural/urban), institutionalization, type of dementia, time consuming
analgesics, GDS, and degree of dependence according to the Barthel index.
4.3. Correlation between PAINAD Scale and Saliva Biomarkers
The polyserial correlation coefficient, both following a simple two-step method and
based on the maximum likelihood estimates method, was used to measure the degree of
correlation between the PAINAD variables (numeric, binary, and recoded) and the levels of
sTNF-RII and sIgA. In the two-step method, the value of the association between PAINAD
(numeric) and sTNF-RII and sIgA was 0.76 (p < 0.001) and 0.56 (p < 0.001), respectively;
whereas the value based on maximum likelihood estimation was 0.99 (p < 0.001) for sTNF-
RII and 0.58 (p < 0.001) for sIgA.
In addition, in the two-step method, the associations between the binary-coded
PAINAD scale score and the sTNF-RII and sIgA levels were 0.85 (p < 0.001) and 0.72
(p < 0.001), respectively. Additionally, according to the likelihood estimation, this ratio was
0.99 (p < 0.001) for sTNF-RII and 0.94 (p < 0.001) for sIgA.
Moreover, in the simple two-step method, the relationship between the recoded
PAINAD variable and sTNF-RII was 0.79 (p < 0.001), whereas it was 0.99 (p < 0.0001) in
the maximum likelihood estimation. In turn, the correlation between recoded PAINAD
and sIgA was 0.70 (p < 0.001) in the two-step model and 0.95 (p < 0.001) according with the
maximum likelihood estimate.
Therefore, all correlations can be considered high and statistically significant, although
in all cases, the largest correlation was between the PAINAD score (numeric, binary, and
recoded) and the sTNF-RII biomarker.
4.4. Regression Models
A binary logistic model was applied using a conditional step-by-step forward proce-
dure to assess which of the two biomarkers had the largest influence on determining the
presence of pain (no pain) in study subjects. In this model, the dependent variable was
the binary PAINAD variable (0 no pain, 1 pain), and the sTNFR-II and sIgA levels were
considered independent variables. The procedure excluded sIgA as a predictor variable in
the model. Thus sTNF-RII was determined as the most influential variable for the prognosis
of pain. Data obtained in the analysis are shown in Table 2.
Table 2. Binary logistic model between the binary PAINAD variable and the sTNFR-II and
sIgA levels.
Variables in the Equation
Dependent Variable:
Binary_PAINAD B Standard Error Wald df Sig. Exp(B)
sTNF-RII (pg/mg prot)
Constant
2.177 1.301 2.801 1 0.094 8.817
−10.469 6.118 2.928 1 0.087 0.000
Nagelkerke R2 0.963. Cox & Snell R2 0.716 Cut-off point 0.5% of well-classified cases 97.3 model sig. 0.000.
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The PAINAD variable was then recoded into three categories (no pain, possible pain,
and pain). In this case, a multivariate logistic model was applied to again determine the
most influential indicator. Tables 3 and 4 show that again the variable sIgA was ruled out
from the model (sig. > 0 0.05).
Table 3. Multivariate logistic model between PAINAD score (three categories) and sTNF-RII and sIgA.
Parameter Estimates










Interception −68.332 2827.925 0.001 1 0.981
sTNF-RII 10.264 0.702 213.580 1 0.000 28667.235 7237.641 113546.716
sIgA 0.001 1.530 0.000 1 0.999 1.001 0.050 20.072
With pain
Interception −77.191 2827.924 0.001 1 0.978
sTNF-RII 10.915 0.000 1 0.000 54977.698 54977.698 54977.698
sIgA 0.002 1.530 0.000 1 0.999 1.002 0.050 20.077
a. The reference category is: no pain.
Table 4. Parameters for adjusting the multivariate logistic model between the PAINAD scale (three
categories) and sTNF-RII and sIgA.
Likelihood Ratio Comparison
Effect
Model Fit Criteria Likelihood Ratio Comparison
-2Log Likelihood of the
Reduced Model Chi-Square df Sig.
Interception 79.552 75.041 2 0.000
sTNF-RII (pg/mg prot) 66.945 62.433 2 0.000
sIgA (ng/mg prot) 5.343 0.831 2 0.660
Nagelkerke R2 0.979. Cox & Snell R2 0.790% of well-classified cases 96.2.
In relation to the original PAINAD variable, Tables 5 and 6 show that the results in
determining the multivariate logistic model were similar to the above mentioned, ruling
out the sIgA variable again.
Table 5. Multivariate logistic model between the original PAINAD score and sTNF-RII and sIgA.
Parameter Estimates
PAINAD a











Interception −61.291 3968.797 0.000 1 0.988
sTNF-RII 9.203 595.872 0.000 1 0.988 9923.542 0.000 b
sIgA 0.001 0.738 0.000 1 0.999 1.001 0.236 04.255
2
Interception −69.780 3968.804 0.000 1 0.986
sTNF-RII 9.801 595.872 0.000 1 0.987 18055.531 0.000 b
sIgA 0.002 0.738 0.000 1 0.998 1.002 0.236 4.256















Interception −164.123 8885.031 0.000 1 0.985
sTNF-RII 15.207 737.434 0.000 1 0.984 4020202.510 0.000 b
sIgA 0.001 0.752 0.000 1 0.999 1.001 0.229 4.368
5
Interception −333.143 20651.032 0.000 1 0.987
sTNF-RII 18.817 788.261 0.001 1 0.981 148569218.102 0.000 b
sIgA 0.001 1.035 0.000 1 0.999 1.001 0.132 7.617
6
Interception −393.108 20877.084 0.000 1 0.985
sTNF-RII 19.192 847.243 0.001 1 0.982 216275110.473 0.000 b
sIgA 0.002 0.805 0.000 1 0.998 1.002 0.207 4.852
8
Interception −414.142 0.000 1
sTNF-RII 19.308 852.322 0.001 1 0.982 242920504.208 0.000 b
sIgA 0.001 0.964 0.000 1 0.999 1.001 0.151 6.622
a. The reference category is: 0. b. A floating-point overflow occurred while calculating this statistic. Therefore, its value is set as a system
loss. c. Numerical score on the PAINAD scale, which can range from 0 (no pain) to 10 (maximum pain) points. Values 3, 7, 9, and 10 are
absent as no subject obtained this score.




Model Fit Criteria Likelihood Ratio Comparison
-2Log Likelihood of the
Reduced Model Chi-Square df Sig.
Interception 178.552 174.056 6 0.000
sTNF-RII 110.324 105.827 6 0.000
sIgA 5.343 0.846 6 0.991
Nagelkerke R2 0.993 Cox & Snell R2 0.916% of well-classified cases 96.2.
5. Discussion
Our results support the usefulness of the PAINAD scale for assessing pain in patients
with advanced dementia, given the correlation between the sTNF-RII and sIgA measure-
ments and the score on the PAINAD scale. Therefore, the PAINAD scale was confirmed
as a simple and feasible tool, but with remarkable precision, that allows to assess pain in
people with dementia and inability to communicate and thus to mitigate the characteristic
underdiagnosis and undertreatment in these patients [29,30]. However, it is necessary to
persuade the health care professional who will conduct the assessment mentioned above
to acquire training for its correct use [20,31].
Similarly, the determination of pain biomarkers in fluids such as the saliva is a promis-
ing strategy [32], especially for patients with advanced dementia and the inability to
communicate, where direct reporting of perceived pain is impossible. In addition, saliva is
a biological sample whose accessibility is significantly less invasive than blood determi-
nations. In this sense, the determination of both sTNF-RII and sIgA in saliva, in line with
the results of other authors, meets the requirements to be considered appropriate for its
implementation in clinical practice because it is safe, relatively simple, reproducible, and
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non- invasive [26]. However, there is a need to clarify the sometimes existence of difficulty
in taking salivary samples, such as xerostomia associated with advanced dementia [33,34].
Regarding the correlation between both biomarkers (sTNF-RII and sIgA) and the
PAINAD scale, based on the results achieved, both should be considered as biomarkers of
pain. Specifically, regarding sTNF-RII levels, it has been shown that between 97.3% and
96.2% of patients with pain on the scale would also have pain according to sTNF-RII. This
result would probably be related to the pain-modulating function of some cytokines [35],
including tumor necrosis factor-alpha (TNF-α), which would explain why an increase in
sTNF-RII, which is a TNF-α receptor, involves an increase in pain based on the PAINAD
scale. However, it should be noted that, in addition to this pain-modulating function,
TNF-α is a pro-inflammatory cytokine involved in the immune response [36]. Additionally,
neuroinflammation plays a significant role in developing dementia and AD [37–40], which
implies high TNF-α levels at baseline in both pain and no pain patients.
The results, therefore, confirm the usefulness of the PAINAD scale for pain assessment
in patients with advanced dementia. Moreover, our results point to the determination of
sTNF-RII in saliva as an effective method by itself and complementary to the PAINAD
scale, if it is desired to objectify the assessment.
Furthermore, the correlation found in our study between the PAINAD scale values and
the sIgA levels has also previously been reported by Sobas et al. (2016) in healthy patients,
which would allow us to establish a link between pain and the pain biomarker sIgA [26].
However, these studies do not point to the mechanisms associating sIgA with pain, and
our study does not show it either. The role of sIgA as an immunoglobulin involved in
protecting the oral mucosa and, consequently, its relationship with oral infections and
inflammatory processes is known [41]. Recent studies also report an association between
periodontal diseases and dementia processes [42–44]. However, we cannot demonstrate
that this relationship occurs in our study because no periodontal diseases were identified
in the subjects studied.
The absence of a relationship between pain and sociodemographic characteristics (sex,
age, marital status, area and institutionalization) could be conditioned by the characteristics
of our sample (patients with advanced dementia). The associations found in previous
studies seem to be related, at least in part, to the psychological component of pain (the
thoughts the person has about what happens to him/her and what he/she feels) [45,46].
The lack of association with clinical characteristics may be because our study subjects
represent a very homogeneous population (with significant cognitive impairment and a
significant level of dependence for basic activities of daily living). This would have made it
difficult to recognize such an association.
Finally, the lack of association between analgesic use and the PAINAD scale could
be related to the scarce and limited analgesic treatment of the study subjects due to the
frequent underdiagnosis and undertreatment of pain in this group that, often, is constricted
to the first step of analgesia in the World Health Organization (WHO) classification [47,48].
Therefore, new studies are required to truly assess whether undertreatment of pain im-
proves after the inclusion of these tools (PAINAD scale and saliva biomarkers) for pain
assessment in clinical practice.
Limitations
The xerostomia present in some subjects has hindered the collection of enough salivary
sample volume for measuring both biomarkers in some subjects. Therefore, the sample
size was relatively lower (n = 54) in the measurement of sIgA. However, statistical analysis
has shown that the number of subjects was sufficient to achieve significant results.
6. Conclusions
The correlation between the PAINAD scale and the sTNF-RII and sIgA pain biomark-
ers reinforce the usefulness of this scale in assessing pain in people with dementia and
inability to communicate. Similarly, the sTNF-RII and sIgA salivary biomarkers are sug-
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gested as efficient and complementary tools of utmost applicability for pain assessment,
and sTNF-RII is most accurately predicting pain in people with advanced dementia, ac-
cording to the PAINAD scores.
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